About hemophilia A
Hemophilia is a rare bleeding disorder caused by deficiency of clotting factors such as VIII and IX. It is an X-linked recessive disorder, which is more prevalent in males than in females. It is estimated that it affects around 400,000 people per year. The two major types of hemophilia are A and B. Hemophilia A, also called as classical hemophilia or factor VIII deficiency hemophilia, is caused by deficiency of clotting factor VIII. It is transmitted genetically from parent to child during birth. Recombinant clotting factors or plasma-derived clotting factors are being developed for the treatment of this disorder.
Technavio's analysts forecast the global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy.
Technavio's report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Hemophilia A Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Hemophilia A Market: Baxter International, Bayer's, CSL Behring, Novo Nordisk and Pfizer
Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen Idec, Catalyst Biosciences, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Grifols, Inspiration Biopharmaceuticals, Kedrion Biopharma, Octapharma, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics and UniQure
Commenting on the report, an analyst from Technavio’s team said: “There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action.”
According to the report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period.
Further, the report states that the high cost of treatment leads to the discontinuation of therapy, thereby hampering market growth.
Baxter International, Bayer's, CSL Behring, Novo Nordisk, Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen Idec, Catalyst Biosciences, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Grifols, Inspiration Biopharmaceuticals, Kedrion Biopharma, Octapharma, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, UniQure
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook